CTOs on the Move

Inteprod

www.inteprod.com

 
Inteprod LLC is a Norristown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.inteprod.com
  • 970 Rittenhouse Rd
    Norristown, PA USA 19403
  • Phone: 610.650.9002

Executives

Name Title Contact Details

Similar Companies

PTPN

PTPN is a Calabasas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mountain Laurel Medical Center

Mountain Laurel Medical Center is a community health center that provides primary health care, wellness promotion, and education to individuals in Garrett County and surrounding areas.

Steadfast Data Systems

Steadfast Data Systems is a Evanston, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evans Analytical Group LLC

Evans Analytical Group (EAG) has been a global leader in surface analysis and materials characterization for over 29 years, delivering innovative analytical services and solutions with uncompromising scientific integrity.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.